Lilly GMP Strategy: Avoid Consent Degree With Open Communication At FDA
Executive Summary
Lilly's ongoing, "open" communication with FDA over good manufacturing practices should help avoid a consent decree, CFO Charles Golden said during the Bear Stearns healthcare conference in New York Sept. 19
You may also be interested in...
Avandaryl Approval On Track Despite Consent Decree, GSK Says
GlaxoSmithKline is confident FDA will approve its diabetes line extension agent Avandaryl on schedule despite the fact that the manufacturing facility for the product is operating under a GMP consent decree
Avandaryl Approval On Track Despite Consent Decree, GSK Says
GlaxoSmithKline is confident FDA will approve its diabetes line extension agent Avandaryl on schedule despite the fact that the manufacturing facility for the product is operating under a GMP consent decree
Lilly Strattera Is First ADHD Agent With Adult Indication, Full-Scale Launch
Lilly's Strattera will be the first ADHD therapy to have a traditional full-scale pharmaceutical launch